Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer.
Cottu
P H
PH
Asselah
J
J
Lae
M
M
Pierga
J-Y
JY
Diéras
V
V
Mignot
L
L
Sigal-Zafrani
B
B
Vincent-Salomon
A
A
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000235:genetics* / Q000628:therapy*; D000069287:Capecitabine; D044584:Carcinoma, Ductal / Q000235:genetics* / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077143:Docetaxel; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D018734:Genes, erbB-2 / Q000235:genetics*; D006801:Humans; D008113:Liver Neoplasms / Q000235:genetics / Q000556:secondary; D008875:Middle Aged; D012074:Remission Induction; D043823:Taxoids / Q000008:administration & dosage; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D000069287:Capecitabine; D000068878:Trastuzumab; D005472:Fluorouracil